Ac-DL-Ala-butylamide | 83210-92-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Ac-DL-Ala-butylamide
• 英文别名: N-acetyl-DL-alanine butylamide；DL-2-Acetamino-propionsaeure-butylamid；N-Acetyl-DL-alanin-butylamid；Propanamide, 2-(acetylamino)-N-butyl-；2-acetamido-N-butylpropanamide
• CAS: 83210-92-8
• 化学式: C₉H₁₈N₂O₂
• mdl: MFCD24388101
• 分子量: 186.254
• InChiKey: XYPPBJSUDCQSOY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.777
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  2-乙酰氨基丙酸乙酯 、 正丁胺 生成 Ac-DL-Ala-butylamide
  参考文献：
  名称：

  New Compounds. Some Acylamino Acid Esters and Amides

  摘要：

  DOI：

  10.1021/ja01176a603

文献信息

• SCN9A antisense pain killer
  申请人：OliPass Corporation

  公开号：US11162104B2

  公开（公告）日：2021-11-02

  The current invention provides peptide nucleic acid derivatives targeting the 3′ splice site of exon 4 in the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce SCN9A mRNA splice variant(s) lacking the SCN9A exon 4 in cells, and are useful to safely treat pains or conditions involving Nav1.7 activity.

  本发明提供了靶向人 SCN9A 前 mRNA 第 4 外显子 3′剪接位点的多肽核酸衍生物。多肽核酸衍生物能有效诱导细胞中缺乏 SCN9A 第 4 号外显子的 SCN9A mRNA 剪接变体，可用于安全治疗涉及 Nav1.7 活性的疼痛或病症。
• HIF 1-ALPHA ANTISENSE OLIGONUCLEOTIDES
  申请人：Olipass Corporation

  公开号：EP3526239B1

  公开（公告）日：2021-11-03
• SCN9A ANTISENSE OLIGONUCLEOTIDES
  申请人：OliPass Corporation

  公开号：US20190218255A1

  公开（公告）日：2019-07-18

  The current invention provides peptide nucleic acid derivatives targeting a part of the human SCN9A pre-mRNA. The peptide nucleic acid derivatives potently induce splice variants of the SCN9A mRNA in cells, and are useful to safely treat pains or conditions involving Na v 1.7 activity.
• EXON SKIPPING BY PEPTIDE NUCLEIC ACID DERIVATIVES
  申请人：OliPass Corporation

  公开号：US20190337987A1

  公开（公告）日：2019-11-07

  A peptide nucleic acid derivative of Formula I is provided to tightly bind to a splice site within a pre-mRNA in a sequence specific manner. Given with excellent cell membrane permeability and strong affinity for RNA, the said peptide nucleic acid derivative induces exon skipping in cells treated with the peptide nucleic acid at sub-femtomolar concentration as “naked” oligonucleotide. The said compound shows therapeutic activity in subjects upon systemic administration even at 1 μg/Kg or less, and therefore is useful to treat a disease or symptom at affordable treatment cost.
• ANDROGEN RECEPTOR ANTISENSE OLIGONUCLEOTIDES
  申请人：OliPass Corporation

  公开号：US20190345202A1

  公开（公告）日：2019-11-14

  Provided are peptide nucleic acid derivatives targeting the 5′ splice site of “exon 5” within the human androgen receptor pre-mRNA. The peptide nucleic acid derivatives potently induce splice variants of the androgen receptor mRNA in cells, and are useful to safely treat dermatological indications or conditions involving androgenic activity upon topical administration.